Jaguar Health Inc reports results for the quarter ended June 30 - Earnings Summary

• Jaguar Health Inc JAGX.OQ reported a quarterly adjusted loss of $10.26​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-101.00. The lone analyst forecast for the quarter was for a loss of $7.13 per share.

• Revenue rose 7.9% to $2.94 million from a year ago; analysts expected $3.27 million.

• Jaguar Health Inc's reported EPS for the quarter was a loss of $10.26​.

• The company reported a quarterly loss of $10.41 million.

• Jaguar Health Inc shares had risen by 2.8% this quarter and lost 89.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Jaguar Health Inc is $16.00, about 83.8% above its last closing price of $2.59

This summary was machine generated from LSEG data August 14 at 08:08 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)